Advertisement

Topics

Halloran announces role as regulatory lead for Curtana’s CT-179 Orphan designation

12:38 EDT 18 Aug 2017 | CentreWatch

Halloran Consulting Group, a national consultancy serving biotech, pharma, & medical device companies with clinical, quality and regulatory compliance projects, announced their role as U.S. regulatory consultants for Curtana Pharmaceuticals. The FDA granted orphan drug designation to CT-179, Curtana Pharmaceuticals’ lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma (GBM) in adults and pediatric high-grade […]

The post Halloran announces role as regulatory lead for Curtana’s CT-179 Orphan designation appeared first on CenterWatch News Online.

Original Article: Halloran announces role as regulatory lead for Curtana’s CT-179 Orphan designation

NEXT ARTICLE

More From BioPortfolio on "Halloran announces role as regulatory lead for Curtana’s CT-179 Orphan designation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...